# Xencor Shares Climb 23.94% on XmAb819 Kidney Cancer Results

By Enna Lee

Canonical URL: https://www.tokenpost.com/news/investing/40904
Published: 2026-10-26T09:46:57.000Z
Updated: 2026-10-26T09:46:57.000Z
Section: Investing

> A Phase 1 study showed a 45.5% response rate in advanced kidney cancer. Xencor plans accelerated discussions with the Food and Drug Administration.

Xencor shares rose 23.94% Monday, Oct. 26, after results from a Phase 1 trial of XmAb819 showed a 45.5% response rate in advanced kidney cancer.

XmAb819 is a drug studied for advanced kidney cancer. Xencor plans accelerated discussions with the Food and Drug Administration (FDA).

The broader U.S. market backdrop was mixed: futures steadied Monday morning after two consecutive weekly declines in major indexes. Oil prices remained elevated, and skepticism over AI capital spending persisted.